These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 22020329

  • 1. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
    Franks SE, Campbell CI, Barnett EF, Siwicky MD, Livingstone J, Cory S, Moorehead RA.
    Oncogene; 2012 Jul 05; 31(27):3298-309. PubMed ID: 22020329
    [Abstract] [Full Text] [Related]

  • 2. Preneoplastic changes persist after IGF-IR downregulation and tumor regression.
    Jones RA, Petrik JJ, Moorehead RA.
    Oncogene; 2010 Aug 26; 29(34):4779-86. PubMed ID: 20543862
    [Abstract] [Full Text] [Related]

  • 3. Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells.
    Saleh S, Thompson DE, McConkey J, Murray P, Moorehead RA.
    BMC Cancer; 2016 Jun 10; 16():359. PubMed ID: 27282619
    [Abstract] [Full Text] [Related]

  • 4. Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice.
    Watson KL, Moorehead RA.
    BMC Cancer; 2013 Aug 07; 13():375. PubMed ID: 23919516
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Murine mammary tumor cells with a claudin-low genotype.
    Campbell CI, Thompson DE, Siwicky MD, Moorehead RA.
    Cancer Cell Int; 2011 Aug 16; 11():28. PubMed ID: 21846397
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.
    Linnerth NM, Siwicky MD, Campbell CI, Watson KL, Petrik JJ, Whitsett JA, Moorehead RA.
    Neoplasia; 2009 Jul 16; 11(7):672-82. PubMed ID: 19568412
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
    Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M.
    Proc Natl Acad Sci U S A; 2013 Apr 02; 110(14):E1301-10. PubMed ID: 23509284
    [Abstract] [Full Text] [Related]

  • 20. The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis.
    Jones RA, Moorehead RA.
    J Mammary Gland Biol Neoplasia; 2008 Dec 02; 13(4):407-13. PubMed ID: 19002570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.